Impaired glucose regulation and neuropathy

Neurobiology of Disease

Volumn , Issue , 2007, Pages 849-858

  Russell, James W ^a   Smith, A G ^b   Singleton, J R ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43449136809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50080-3     Document Type: Chapter

References (21)

1. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., Wilson D.M., O'Brien P.C., Melton L.J.3rd, and Service F.J. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic N. Neurology 1993, 43:817-824.
2. Singleton J.R., Smith A.G., Russell J.W., Feldman E.L. Microvascular complications of impaired glucose tolerance. Diabetes 2003, 52:2867-2876.
3. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., Kitzmiller J., Knowler W.C., Lebovitz H., Lernmark A., Nathan D., Palmer J., Rizza R., Saudek C., Shaw J., Steffes M., Stern M., Tuomilehto J., Zimmet P.;, the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26(11):3160-3167.
4. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M.;, the Diabetes Preven-tion Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403.
5. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., Hu Z.X., Lin J., Xiao J.Z., Cao H.B., Liu P.A., Jiang X.G., Jiang Y.Y., Wang J.P., Zheng H., Zhang H., Bennett P.H., Howard B.V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20(4):537-544.
6. Hiltunen L., Laara E., Keinanen-Kiukaanniemi S. Changes in glucose tolerance during three years' follow-up in an elderly population. Public Health 1999, 113(4):181-184.
7. Russell J.W., Kaminsky A.J. Oxidative injury in diabetic neuropathy. Nutrition and Diabetes: Pathophysiology and Management 2005, 381-397. Taylor & Francis, Boca Raton, FL. E. Opara (Ed.).
8. Lindstrom J., Louheranta A., Mannelin M., Rastas M., Salminen V., Eriksson J., Uusitupa M., Tuomilehto J.;, the Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26(12):3230-3236.
9. Cowell R.M., Russell J.W. Peripheral neuropathy and the Schwann cell. Neuroglia 2004, 573-585. Oxford University Press, New York. H. Kettenmann, B.R. Ransom (Eds.).
10. Vincent A.M., Olzmann J.A., Brownlee M., Sivitz W.I., Russell J.W. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 2004, 53:726-734.
11. Cowell R.M., Russell J.W. Nitrosative injury and antiox-idant therapy in the management of diabetic neuropathy. J. Investig. Med. 2004, 52(1):33-44.
12. Russell J.W., Sullivan K.A., Windebank A.J., Herrmann D.N., Feldman E.L. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol. Dis. 1999, 6:347-363.
13. Russell J.W., Cowell R.M., Feldman E.L. Neuronal and Schwann cell death in diabetic neuropathy. The Clinical Management of Diabetic Neuropathy 2006, Humana Press, Totowa, NJ. A. Veves, R. Malik (Eds.).
14. Uehara K., Yamagishi S., Otsuki S., Chin S., Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabeti. Diabetes 2004, 53(12):3239-3247.
15. Vinik A.I., Bril V., Kempler P., Litchy W.J., Tesfaye S., Price K.L., Bastyr E.J.3rd;, the MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-c. Clin. Ther. 2005, 27(8):1164-1180.
16. Berent-Spillson A., Robinson A., Golovoy D., Slusher B., Rojas C., Russell J.W. Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. J. Neurochem. 2004, 89:90-99.
17. Haslbeck K.M., Schleicher E., Bierhaus A., Nawroth P., Haslbeck M., Neundorfer B., Heuss D. The AGE/RAGE/NFκB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp. Clin. Endocrinol. Diabetes 2005, 113(5):288-291.
18. Vincent A.M., Brownlee M., Russell J.W. Oxidative stress and programmed cell death in diabetic neuropathy. Ann. N Y. Acad. Sci. 2002, 959:368-383.
19. Wellmer A., Misra V.P., Sharief M.K., Kopelman P.G., Anand P. A double-blind placebo-controlled clin-ical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J. Peripher. Nerv. Syst. 2001, 6(4):204-210.
20. Feldman E.L., Stevens M.J., Russell J.W., Greene D.A. Somatosensory neuropathy. Ellenberg and Rifkin's Diabetes Mellitus 2003, 771-788. McGraw-Hill Professional, New York. D. Porte Jr., R.S. Sherwin, H. Rifkin (Eds.).
21. Russell J.W., Peltier A., Sheikh K., Howard J., Goldstein J., Smith A.G., Feldman E.L., Singleton J.R. Autonomic dysfunc-tion in subjects with impaired glucose tolerance. J. Peripher. Nerv. Syst. 2005, 10:78.